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Background:  Radioactive iodine (RAI) ablation is considered in the 
postsurgical management of differentiated thyroid carcinoma (DTC). The aim of 
this study was to investigate the effectiveness of low dose (30 mCi) RAI ablation 
and the factors associated with RAI success. 
Methods: A retrospective study was conducted on 691 patients who 
received low dose RAI ablation after total thyroidectomy. The success of the first 
RAI ablation was defined as no remnant on the whole body scan with preablative 
stimulated thyroglobulin (s-Tg) <2.0ng/ml at the second time of RAI administration. 
Patient demographics, pathologic features, laboratory test, and RAI ablation result 
were collected. 
Results:  Low dose RAI ablation was successful in 431 patients (62.3%) 
after the first RAI therapy. The first RAI failure was associated with multiplicity 
(39.3% vs 47.1%, p=0.045) and bilaterality (23.1% vs 30.1%, p=0.041) of primary 
tumor, coexisting Hashimoto thyroiditis (HT; 25.5% vs 40.8%, p<0.001), and 
higher s-Tg level (1.5±2.4 vs 6.5±19.0, p<0.001). There were no significant 
differences in age, sex, and pathologic features of tumor including size. 
On multivariate analyses, both coexisting HT and preablative s-Tg retained 
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statistical significance. The relative risk (RR) of first RAI failure with coexisting 
HT was significantly increased at 2.86 (95% confidence interval [CI] 1.95, 4.17, 
p<0.001). The RR along preablative s-Tg level was also increased, with an RR of 
1.23 (95% CI 1.15, 1.31, p<0.001). 
Conclusions: Success of low dose RAI ablation at the first time was influenced 
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Radioactive iodine (RAI) ablation after total thyroidectomy is usually considered 
for patients with differentiated thyroid carcinoma (DTC). Ablation of the small 
amount of residual normal thyroid may facilitate the early detection of recurrence 
based on serum thyroglobulin measurement and/or RAI whole body scan (WBS).1 
The post-RAI scan obtained at the time of remnant ablation may influence initial 
staging by identifying previously undiagnosed disease, especially in the lateral neck. 
Furthermore, from a theoretical point of view, this first dose of RAI may also be 
considered adjuvant therapy because of the potential tumoricidal effect on persistent 
thyroid cancer cells remaining after appropriate surgery in patients at risk for 
recurrence or disease specific mortality. 
According to the American thyroid association guideline, RAI ablation is 
recommended for 1) all patients with gross extrathyroidal extension or primary 
tumor size > 4cm, and 2) selected patients with 1-4cm thyroid cancers confined to 
the thyroid, lymph node (LN) metastases, or other higher risk features.1 No specific 
amount of activity is preferred, and the recommendation is to use “the minimum 
activity (30-100 mCi) necessary to achieve successful remnant ablation.” 
There are several advantages to both the patient and healthcare provider for using a 
lower activity of RAI, including less time in isolation, a shorter hospital stay, 
reduced exposure of RAI to the environment, and lower financial cost.2 Furthermore, 
RAI ablation is associated with an increased risk of second primary malignancies; 
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the lower the activity administered the lower the risk.3 However, there are some 
controversies whether low dose RAI is feasible to all DTC patients. The aim of this 
study was to investigate the effectiveness of low dose (30 mCi) RAI ablation and 





From August 2004 to July 2012, a total of 738 patients with DTC underwent total 
thyroidectomy received low dose RAI ablation in Seoul National University 
Bundang Hospital. After we reviewed all patients in this cohort, we excluded 47 
patients: 42 with a thyroid stimulating hormone (TSH) below 30mIU/L at the first 
or second time of ablation, 3 with missing preablative laboratory tests, and 2 in 
whom LN dissection was performed between the first and second RAI ablation.  
In the study population of 691 patients, a WBS using 1110 MBq (30 mCi) of 131I 
and stimulated thyroglobulin (s-Tg) measurement was performed two or three 
months after surgery. A second dose was given 6-12 months after the first low dose. 
The success of the first RAI ablation was defined as no remnant on the WBS with 
low serum s-Tg (< 2.0ng/ml) at the second time of RAI administration. 
One hundred three patients with high thyroglobulin antibody (≥ 150 uU/ml) were 
identified when a thyroglobulin antibody (TgAb) level < 150 uU/ml was considered 
as negative interference. To exclude the possible interference of the TgAb, subgroup 
analysis was performed in the low TgAb (< 150 uU/ml) patients. 
Patient demographics, pathologic features, laboratory test, and RAI ablation result 




At the time of the first RAI ablation, mean patient age was 47.8 ± 10.5 years and 
female-to-male ratio was 4 : 1 (Table 1). Total thyroidectomy without lymph node 
(LN) dissection was performed in 18.2% (126/691) of patients and 81.7% of 
patients underwent combined central LN dissection. Mean tumor size was 1.19 ± 
0.94 cm and extrathyroidal extension was found in 69.1% of tumors. LN metastasis 
was associated with 42.3% of patients. Preablative TSH, s-Tg, and TgAb level were 
132.5 ± 75.1 uU/ml, 3.3 ± 12.0 ng/ml, and 89.7 ± 166.7 IU/ml, respectively. 
Table 2 showed clinicopathological features of the first RAI success and failure 
group. The first low dose RAI ablation was successful in 431 (62.3%) patients. Two 
hundred sixty patients showed remnant thyroid activity on the second WBS and/or 
high serum s-Tg level after the first RAI ablation. On univariate analysis, the first 
low dose RAI success was associated with multiplicity (39.3% vs 47.1%, p=0.045) 
and bilaterality (23.1% vs 30.1%, p=0.041) of primary tumor. Coexisting 
Hashimoto thyroiditis (HT; 25.5% vs 40.8%, p<0.001) in the pathologic exam was 
related to the lower rate of successful RAI ablation. Also, preablative s-Tg level was 
significantly lower in the first RAI success group than the first RAI failure group 
(1.5 ± 2.4 vs 6.5 ± 19.0, p<0.001). There were no significant differences in age, 
sex, and pathologic features of tumor including size. 
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Table 1 Patient characteristics 
Characteristics  
Sex (male : female) 138 (20.0%) : 553 (80.0%) 
Age (years) 47.8±10.5 (range 15–77) 
Combined central LN dissection 565/691 (81.8%) 
Pathologic features 
Tumor size (cm) 1.19±0.94 (0.2-12.5) 
Encapsulation (None/Partial/Complete) 75.5%/14.5%/9.8% 
Capsular invasion 46/640 (6.7%) 
Lymphatic invasion 82/687 (11.9%) 
Vascular invasion 17/687 (2.5%) 
Extrathyroidal extension  
None/Microscopic/Macroscopic 30.9%/60.7%/8.4% 
Resection margin involvement 40/690 (5.8%) 
LN metastasis 292/690 (42.3%) 
Multiplicity 291/689 (42.2%) 
Bilaterality 177/688 (25.7%) 
Coexisting Hashimoto thyroiditis 215/688 (31.3%) 
Laboratory findings 
Pre-ablation TSH 132.5±75.1 
Stimulated Tg 3.3±12.0 
TgAb 89.7±166.7 
LN lymph node; TSH thyroid stimulating hormone; Tg thyroglobulin; TgAb 
thyroglobulin antibody  
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On multivariate analyses, both coexisting HT and preablative s-Tg retained 
statistical significance. The relative risk (RR) of first RAI failure with coexisting 
HT was significantly increased at 2.86 (95% confidence interval [CI] 1.95, 4.17, 
p<0.001). The RR along preablative s-Tg level was also increased, with an RR of 
1.23 (95% CI 1.15, 1.31, p<0.001). 
To exclude the variation of the s-Tg measurement by TgAb, statistical analysis was 
performed again in low TgAb patients (Table 3). Multivariate analysis showed that 
prealbative s-Tg (RR 1.23, 95% CI 1.15, 1.31, p<0.001) and coexisting HT (RR 
2.76, 95% CI 1.79, 4.24, p<0.001) were associated with the success of the first RAI 




Table 2 Comparison of 1st low dose RAI success group and failure group 
Characteristics 
1st group  
(n=431) 
≥2nd group  
(n=260) 
P value 
Sex (% of female) 81.4 77.7 0.233 
Age (years) 48.3±10.4 47.1±10.6 0.149 
Combined central LN dissection (%) 83.1 79.6 0.256 
Pathologic features 
Tumor size (cm) 1.19±0.84 1.20±1.09 0.893 
Encapsulation (%)   0.491 
None/Partial/Complete 74.5/14.5/11.0 77.0/14.8/8.2  
Capsular invasion 7.5 5.4 0.298 
Lymphatic invasion 10.9 13.6 0.293 
Vascular invasion 2.8 1.9 0.490 
Extrathyroidal extension   0.663 
None/Microscopic/Macroscopic 32.1/59.5/8.4 28.8/62.7/8.5  
Resection margin involvement 6.0 5.4 0.718 
LN metastasis 42.6 41.9 0.870 
Multiplicity 39.3 47.1 0.045 
Bilaterality 23.1 30.1 0.041 
Coexisting Hashimoto thyroiditis 25.5 40.8 <0.001 
Laboratory findings 
Pre-ablation TSH 130.1±76.0 136.3±73.5 0.295 
Stimulated Tg 1.5±2.4 6.5±19.0 <0.001 
TgAb 82.1±149.8 102.4±191.2 0.146 
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Table 3 Comparison of 1st low dose RAI success in the low TgAb patients 
Characteristics 
1st group  
(n=380) 
≥2nd group  
(n=211) 
P value 
Sex (% of female) 80.3 75.4 0.164 
Age (years) 48.4±10.3 47.0±10.8 0.122 
Combined central LN dissection (%) 92.1 89.6 0.298 
Pathologic features 
Tumor size (cm) 1.17±0.84 1.17±0.87 0.960 
Encapsulation (%)   0.503 
None/Partial/Complete 73.7/14.6/11.7 76.2/15.2/8.6  
Capsular invasion 8.0 5.2 0.210 
Lymphatic invasion 10.8 13.8 0.283 
Vascular invasion 2.6 1.9 0.576 
Extrathyroidal extension   0.763 
None/Microscopic/Macroscopic 31.7/59.6/8.7 29.9/62.6/7.6  
Resection margin involvement 6.1 5.2 0.669 
LN metastasis 40.6 46.0 0.209 
Multiplicity 38.5 42.5 0.360 
Bilaterality 22.7 28.1 0.145 
Coexisting Hashimoto thyroiditis 19.9 31.8 0.001 
Laboratory findings 
Pre-ablation TSH 126.9±72.8 132.3±71.6 0.391 





There are some controversies whether low dose RAI ablation is effective to all DTC 
patients. However, there is no direct evidence that radioiodine ablation of the 
thyroid remnant reduces the risk of recurrence or death in those with DTC.2 It could, 
therefore, be argued that in the absence of such evidence the lowest activity would 
be appropriate. 
The success rates of low and high dose RAI ranged from 10% to 80% and from 50 
to 100%, respectively.4-7 From a meta-analysis performed in 2000, a high dose RAI 
resulted in 27% increase of RAI success than low dose one.8 However, most of the 
success rate estimates from the low activity studies were based on fewer than 50 
patients, and the success rate in the two largest studies was approximately 70%.9, 10 
Furthermore, two randomized prospective trials published in 2012 showed that the 
success rates were similar between low dose and high dose RAI.11, 12 The success 
rate of the first low dose RAI was 62.3% in our study, which was in agreement with 
previous studies. 
Many studies have investigated the factors influencing the rate of successful 
ablation, including postsurgical remnant size, preablative serum thyroglobulin, 
method of TSH stimulation, and the use of a preablation scan; nevertheless, there 
were no definitive predictive factors except preablative s-Tg.2 Not only small 
sample sizes, but also confounders including retrospective nature of these studies 
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and lack of blinding would have contributed to the variability in the associated 
factors. In the present study, we found that preablative s-Tg and coexisting HT were 
associated with the success of RAI. 
To our best knowledge, this is the first report that coexisting HT can be related to 
the success of RAI. There are some possible explanations how coexisiting HT 
would have contributed to the failure of the first RAI ablation. First, thyroid tissue 
with HT scored significantly lower positive sodium-iodide symporter (NIS) 
membrane staining than normal thyroid tissue.13 In a recent clinical study, patients 
with thyroiditis had a median 0.0089% RAI uptake, whereas patients without 
thyroiditis had a median 0.0180%; although there was no statistical significance.14 
Lower NIS expression can be one of the explanations of the RAI failure in 
coexisting HT. Second, HT on histology can be frequently associated with 
thyroglobulin antibody (TgAb) and therefore mistakenly low or undetectable s-Tg.15 
As TgAb disturbed the precise measurement of the s-Tg, we performed subgroup 
analyses of patients with low TgAb; the association between HT and the first RAI 
failure was significant in the subgroup analysis. 
In conclusion, success of low dose RAI ablation at the first time was influenced by 
coexisting HT and preablative s-Tg. However, we do not understand the exact 
mechanism how coexisting HT increases RAI ablation failure. Further investigation 
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국   
 
: 사 요 드 잔여 갑상  거술  분  갑상  암 수술 후 
추가 인 료  고 다. 본 연구에 는 용량 (30 mCi) 
사 요 드 여에 른 잔여 갑상  거술  효과를 인하고, 잔여 
갑상  거술  공과 실패에  요인  규명하는 것  목표  
한다. 
상 자  법: 분  갑상  암  갑상   술   후, 
용량 사 요 드 여를  691명  자를 상  후향  
연구를 시행하 다. 첫 회 잔여 갑상  거술  공  2회 료 직  
검사상 청 자극 갑상 르몬 수 가 2.0ng/ml이하이며, 2회 료 후 
신 스캔에  잔여 갑상  조직이 보이지 않는 경우  하 다. 
결과: 용량 사 요 드 잔여 갑상  거술  431명 (62.3%)  
자에  첫 회에 공한 것  나타났다. 단변량 분  시행하  , 
용량 사 요 드 첫 회 여 시 잔여 갑상  거  실패  계  
요인  종양  다  (39.3% vs 47.1%, p=0.045), 양  (23.1% 
vs 30.1%, p=0.041), 동  하시모토 갑상 염 (25.5% vs 40.8%, 
p<0.001)  사 요 드 료  자극 갑상  불린 (1.5±2.4 vs 
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6.5±19.0, p<0.001)과 이 심 었다. 상 자  나이, 별 
 종양  크 를 롯한 다른 병리학  인자   찰 지 
않았다. 
다변량 분  시행하  , 동  하시모토 갑상 염  
사 요 드 료  자극 갑상  불린 만이 통계  한 
것  나타났다. 하시모토 갑상 염이 동 어 있  , 상  험도는 
2.86  (95% 신뢰구간, 1.95, 4.17, p<0.001)  계산 었다. 
사 요 드 료  자극 갑상  불린에 르는 상  험도는 
1.23  (95% 신뢰구간, 1.15, 1.31, p<0.001) 나타났다. 
결 : 잔여 갑상  거를 한 첫 회  용량 사 요 드 여  
공  하시모토 갑상 염  동   사 요 드 료  자극 
갑상  불린 수  이 있었다. 하시모토 갑상 염과 
사 요 드 료  계에 한 추가 인 연구가 필요하다. 
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